Situated in Lexington, Massachusetts, CURIS Inc., often referred to as CRIS, is a pioneering biotechnology company dedicated to developing and commercializing innovative drugs for the treatment of human cancers. Developing cancer-targeted therapies is no easy feat; however, Curis Inc. has proven to be a leader in the field, integrating the cutting-edge medical sciences with a deep operational knowledge that pushes the boundaries of the health sector.
Established in 2000, CURIS INC. has a rich history in the pharmaceutical industry. It is most widely known for the development of Erivedge® (vismodegib), an advanced cancer treatment for adults with basal cell carcinoma that has metastasized to other parts of the body or cannot be treated with surgery or radiation. CURIS worked in collaboration with Genentech (a member of the Roche Group) on the development of this drug, which was approved by FDA in 2012. This demonstrates CURIS INC.'s commitment to innovation and collaboration, which is a fundamental cornerstone of their work.
Currently, Curis is targeting the most hard-to-treat cancers through the development of a pipeline of next-generation targeted cancer therapies, including Fimepinostat, CA-4948, and CI-8993. These treatments are designed to inhibit key cancer-driving kinases and pathways in tumor cells, disrupting their growth and spread.
Fimepinostat is a unique, small-molecule drug aimed at treating hematologic cancers. CA-4948 is an oral small molecule designed to inhibit the IRAK4 kinase, a key protein in the toll-like receptor (TLR) and Interleukin-1 receptor (IL-1R) signaling pathways. CI-8993 is an antibody for the treatment of solid tumors and hematologic cancers, which successfully inhibits the VISTA checkpoint, a mechanism that cancers can use to hide from the immune system.
Publicly traded as CRIS on the NASDAQ, CURIS INC. continues to expand its strategic collaborations to move its pipeline of novel therapeutics closer to regulatory approval. It also enjoys the continued support of its investors which fuels its work.
In essence, the dynamic and innovative work of CURIS Inc. is helping to create a new frontier in cancer treatment. Their relentless drive for improved patient treatment outcomes combined with their scientific and operational acumen make them a key player in the world of oncology. With continuing research and development, their innovative cancer therapies will likely benefit patients around the globe.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Curis, Inc. (Nasdaq: CRIS) has secured $8.5 million in private financing to fund operations through an initial December 2026 clinical readout for its leukemia candidate, emavusertib. This financing, which includes reductions in warrant exercise prices, is critical as the company has insufficient cash for the next 12 months and faces ongoing funding pressures. The proceeds will specifically support the TakeAim CLL Phase II study of emavusertib, an IRAK4 and FLT3 inhibitor, in combination with zanubrutinib.
Curis Inc (CRIS) has announced an $8.5 million stock and warrant offering to institutional healthcare investors, involving 16,666,680 shares and an equal number of warrants at $0.51 per share, with warrants exercisable at $0.60. The company, which is a clinical-stage biotech focused on cancer therapies, is facing significant financial challenges, including ongoing losses and negative cash flow. Despite a low Price-to-Sales ratio suggesting deep undervaluation, its GF Score of 56 indicates a mixed fundamental profile with weak profitability, cautioning investors about potential risks.
HC Wainwright & Co. has reaffirmed its 'Buy' rating for Curis (CRIS), maintaining a price target of $43.00, despite the company's current unprofitability and moderate GF Score™ of 57/100. Although Curis is considered significantly undervalued by GuruFocus's GF Value™ at $20.18 compared to its current price of $1.82, a cautious approach is advised due to its financial challenges and mixed sentiment from gurus and insiders. The biotech company, focused on oncology therapies, shows promising growth potential but faces profitability issues.
Curis Inc. (CRIS) reported a second-quarter loss of $8.6 million, which translates to a loss of $4.02 per share. This information was generated by Automated Insights using data from Zacks Investment Research.